Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
RPTH Journal shared on LinkedIn:
”Comparative safety of hemophilia therapies in Canada
Real-world comparative safety data for hemophilia therapies remain limited.
This study leverages national registry data to better understand adverse drug reactions across commonly used treatments using Canadian registry data over 5 years
- Allergic reactions were the most frequently reported adverse drug reactions
- A higher number of reported events was observed with emicizumab, although novelty bias cannot be excluded
- No inhibitor development was reported with emicizumab or bypassing agents
These findings provide important real-world insights into the relative safety of therapies used in hemophilia A and B, while highlighting the need for continued pharmacovigilance as treatment landscapes evolve.”
Read the full article here.
Article: Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study
Authors: Omotola Olasupo, Emma Iserman, Arun Keepanasseril, Quazi Ibrahim, Zainab Salim Ali Al-Housni, Federico Germini, Jean-Eric Tarride, Lawrence Mbuagbaw, Shannon Jackson, Ingrid Blydt-Hansen, Michelle Bech, Celina Woo, Mark Belletrutti, Alfonso Iorio, Davide Matino: the Association of Hemophilia Clinic Directors of Canada (AHCDC)
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 15:07The New 2026 Board of Directors of World Federation of Hemophilia
-
May 12, 2026, 15:07Eve Justason: Presenting our Research on VWD and Women’s Health at the AHCDC Symposium
-
May 12, 2026, 14:57Marcel Miron-Celis: The Largest Cohort Ever Studied on Perioperative Management of Thrombotic APS
-
May 12, 2026, 14:53Wrapping up the 2026 CE Meetings Season with Our Physical Therapists CE Meeting in Chicago – Hemophilia Alliance
-
May 12, 2026, 14:53Melissa Hollo: Using AI to Identify Iron Deficiency Anemia Months Earlier
-
May 12, 2026, 14:50Giuseppe Biondi Zoccai: Comparing vFFR-Guided and FFR-Guided Revascularization in Intermediate Coronary Lesions
-
May 12, 2026, 14:48Happy Mother’s Day to All the Amazing GT Moms- Glanzmann’s Research Foundation, Inc.
-
May 12, 2026, 14:46Ifeanyichukwu Ifechidere: DOAC Interference in Coagulation Tests – Are You Spotting It?
-
May 12, 2026, 14:46Yusra Iqbal: What Hemophilia Teaches Us About Modern Hematology